Clínica Médica

Impacto da doença pulmonar obstrutiva crônica e fatores de risco a ela atribuídos em 204 países e territórios, 1990-2019: resultados do Global Burden of Disease Study 2019.

4 Ago, 2022 | 14:28h

Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019 – The BMJ

Comunicado de imprensa: Chronic lung disease remains major public health problem – BMJ Newsroom

 

Comentário no Twitter

New research finds that despite the decreasing burden of COPD, this disease remains a major public health problem, especially in countries with a low sociodemographic index https://t.co/uUkQYCSmBY

— The BMJ (@bmj_latest) July 30, 2022

 

---

M-A | Agonistas receptores de GLP1 estão associados com risco aumentado de progressão de retinopatia em pacientes com diabetes tipo 2.

4 Ago, 2022 | 14:26h

Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link para o resumo – $ para o texto completo)

Comentário: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues

 

---

Estudo de coorte retrospectiva | Síncope e o risco de subsequente de acidente automobilístico.

4 Ago, 2022 | 14:25h

Syncope and the Risk of Subsequent Motor Vehicle Crash: A Population-Based Retrospective Cohort Study – JAMA Internal Medicine (gratuito por tempo limitado)

Editorial: Driving Safety After an Acute Illness—This Is Our Lane – JAMA Internal Medicine (gratuito por tempo limitado)

 

Comentário no Twitter

"I fainted…am I safe to drive?" Study found that 9,223 drivers with an ED visit for syncope had subsequent crash risks no different than controls, suggesting more stringent driving restrictions might not be justified. https://t.co/T0GUJ63Nci

— JAMA Internal Medicine (@JAMAInternalMed) August 1, 2022

 

---

Estudo randomizado | Segurança e eficácia da tirzepatida como adição à medicação anti-hiperglicêmia oral única em pacientes com diabetes tipo 2 no Japão.

4 Ago, 2022 | 14:09h

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Ver também (nota: a dose de dulaglutida usada neste estudo foi provavelmente subótima): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis – Diabetologia

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem

— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022

 

---

M-A | Eficácia de uma dieta restritiva na síndrome do intestino irritável.

4 Ago, 2022 | 14:05h

Efficacy of a Restrictive Diet in Irritable Bowel Syndrome: A Systematic Review and Network Meta-analysis – Korean Journal of Gastroenterology

Comentário: Gluten-Free, Low FODMAP Diets Beneficial for IBS Symptoms – HCPLive

Conteúdos relacionados:

Diet or medication in primary care patients with IBS: the DOMINO study – a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute – Gut

AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review – Gastroenterology

RCT: Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the low FODMAP diet and the gluten-free diet.

10 mistakes in dietary management of irritable bowel syndrome and how to avoid them.

Supplement: Irritable bowel syndrome and related conditions.

RCT: FODMAPs, but not gluten, elicit modest symptoms of irritable bowel syndrome.

RCT: Among patients with diarrhea-predominant irritable bowel syndrome, a low FODMAP diet achieved earlier symptomatic improvements in stool frequency and excessive wind.

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

Guidelines for the treatment of irritable bowel syndrome

ACG Clinical Guideline: Management of irritable bowel syndrome

M-A: Efficacy of a low-FODMAP diet in adult irritable bowel syndrome

 

---

Revisão | Tratamento da descompensação hepática na doença hepática avançada (comprometimento renal, insuficiência hepática, insuficiência suprarrenal e complicações cardiopulmonares).

4 Ago, 2022 | 14:02h

Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications) – Clinical Drug Investigation

 

---

Revisão | Doenças que podem se apresentar de forma semelhante à dor ciática.

4 Ago, 2022 | 14:01h

Sciatica Mimics – emDocs

 

---

Revisão | Manifestações cutâneas da lesão renal aguda.

4 Ago, 2022 | 14:00h

Cutaneous manifestations of acute kidney injury – Clinical Kidney Journal

 

---

Revisão | Tratamento da lesão renal aguda em pacientes oncológicos.

4 Ago, 2022 | 13:59h

Treatment of acute kidney injury in cancer patients – Clinical Kidney Journal

Conteúdos relacionados:

Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity – Nephron

Acute Kidney Injury in Critically Ill Patients with Cancer – Clinical Journal of the American Society of Nephrology

Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents – Kidney Research and Clinical Practice

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer – Kidney International

 

---

Estudo randomizado | Gastroplastia endoscópica para tratamento de obesidade classes 1 e 2.

2 Ago, 2022 | 13:28h

Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial – The Lancet (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

MERIT trial suggests endoscopic sleeve gastroplasty should be considered as a synergistic weight loss intervention for patients with class 1 or class 2 obesity.

Find out more: https://t.co/FWeXeWbBF0 pic.twitter.com/W6qUKW92hR

— The Lancet (@TheLancet) July 30, 2022

 

---